GSK_ Annual_Report_2021-22

GlaxoSmithKline Pharmaceuticals Limited | Annual Report 2021-22 32 The financial year 2021-22 saw six of your Company’s vaccines featuring amongst the top 15 vaccines in the self-pay market (IQVIA MAT March 2022). Though the vaccines self-pay market is estimated to be over ` 2,285 crores, it is currently not reflecting any value growth (IQVIA MAT March 2022) on account of the slower uptake of vaccination during the Covid waves. Your Company launched vaccination awareness campaigns during the year. Former captain of the Indian national cricket team and prolific scorer of sixes, MS Dhoni, featured in the 6 in 1 vaccination campaign to raise awareness about combination vaccination with the tagline ‘Less injections, less pain’ for infants. Also featured was Kareena Kapoor Khan, Indian actress and an aspirational icon for mothers, in the Health Ka Passport campaign to raise awareness about routine immunisation for children. During the year, we launched a new vaccination awareness website (www.myvaccinationhub.co.in ) that provides parents with vaccination related information. It also has an interactive vaccination tracker tool, reminding users about missed or upcoming vaccinations. An innovative and industry-first HCP vaccine ordering app called VaxiKart was also launched. This app enables HCPs to order GSK vaccines from their preferred distributors. We plan to grow our vaccines business by optimising our portfolio and expanding into newer segments. During the year, we got approval for Herpes Zoster (Shingrix) vaccine for prevention of Herpes Zoster (HZ) and Post-Herpetic Neuralgia (PHN) it causes in adults over 50 years of age. Its launch plans are currently underway. Specialty Nucala is the first anti-IL5 drug launched in India (March 2019) for patients suffering from severe eosinophilic asthma (SEA) in adults. Since its launch, Nucala has positively impacted many patients’ lives across India by reducing exacerbations and hospitalisations, helping patients to reduce and even stop their oral corticosteroids. We also launched the Nucala auto-injector formulation in June 2021 that enables patients to self-administer Nucala without the need for hospital visits. The auto- injector provided much needed compliance and ease during the pandemic-induced travel restrictions. The commercial and medical teams have actively engaged pulmonologists in the country to disseminate the robust clinical and real-world evidence of Nucala. During the year, we organised RespiTalk roundtable meetings and forums led by experts on Severe Asthma across India, to increase understanding regarding the diagnosis of severe eosinophilic asthma, along with choosing the right treatment options based on phenotyping. We launched Trelegy Ellipta in India, the country’s first single inhaler triple therapy (SITT) in a once-daily regime for chronic obstructive pulmonary disease (COPD) patients. The product was approved by the Drugs Controller General of India (DCGI) as a maintenance treatment to prevent and relieve symptoms associated with COPD patients aged 18 and above. Supply chain and manufacturing excellence Our manufacturing facility in Nashik, along with our Contract Manufacturing Organisations (CMOs), are consistent with our pursuit of excellence, ensuring that we tided over supply chain disruptions caused by the pandemic, to provide unhindered supply of products to patients. We de-risked operations by enhancing capabilities of existing CMOs and developing alternate product sources in vicinity of demand nodes and devising business continuity plans including re-aligning resources to execute them. Some of the key highlights were: • Over 3 million safe man-hours without reportable illnesses • Over 0.7 million safe man-hours without reportable injuries • Installed 100 KWP Solar PV System Increase in production capabilities, particularly for products such as Calpol and Eltroxin, expansion of our fleet count and the continued measures of Covid- appropriate behaviours at each of our CFAs were some of the hallmarks that ensured each link of our supply chain remained resilient to ensure last-mile connectivity. Warehousing and distribution Responding to the unprecedented challenges during the year, the warehousing and distribution team moved with agility, collaborating with our vast network of stockists, warehouses, and contract manufacturing facilities. This not only improved access to quality healthcare, but also ensured that the supply chain network was not disrupted during the lockdown period. The warehousing and distribution network comprising of more than 30 contract manufacturing facilities, 26 warehouses and 6,000 stockists continued to provide high levels of customer service on time. Directors’ Report